{"filing":{"accession_number":"0001628280-26-053878","cik":"0001894562","ticker":"PRME","company_name":"Prime Medicine, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"prme-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1894562/000162828026053878/prme-20260806.htm"},"events":[{"id":25869,"run_id":23486,"accession_number":"0001628280-26-053878","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Prime Medicine issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, including R\u0026D expenses ($33.4M), G\u0026A expenses ($11.0M), net loss ($42.1M), and cash position ($108.8M). The filing includes condensed consolidated financial statements and is furnished under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure of quarterly financial results and business highlights is a classic earnings release event.","company_name":"Prime Medicine, Inc.","ticker":"PRME","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26803,"accession_number":"0001628280-26-053878","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Prime Medicine issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, including R\u0026D expenses ($33.4M), G\u0026A expenses ($11.0M), net loss ($42.1M), and cash position ($108.8M). The filing includes condensed consolidated financial statements and is furnished under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure of quarterly financial results and business highlights is a classic earnings release event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:39:58.352552+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26803,"accession_number":"0001628280-26-053878","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Prime Medicine issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, including R\u0026D expenses ($33.4M), G\u0026A expenses ($11.0M), net loss ($42.1M), and cash position ($108.8M). The filing includes condensed consolidated financial statements and is furnished under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure of quarterly financial results and business highlights is a classic earnings release event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:39:58.352552+00:00","company_name":"Prime Medicine, Inc.","ticker":"PRME","filing_date":"2026-08-06"}]}